Trial Profile

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
Indications Hodgkin's disease
Focus Registrational; Therapeutic Use
Acronyms ECHELON-1
Sponsors Seagen; Takeda; Takeda Oncology

12 Mar 2025 Planned End Date changed from 13 Jan 2026 to 20 Jan 2026.
04 Jun 2024 Results demonstrating Seven-year overall survival analysis from ECHELON-1 study, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
14 May 2024 According to a Takeda media release, data from this study will be presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com